Exploiting genomics, genetics and chemistry to combat antibiotic resistance

Nature Reviews Genetics

Volumn 4, Issue 6, 2003, Pages 432-441

  Hughes, Diarmaid ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL CARRIER PROTEIN; ACYLTRANSFERASE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BACTERIAL DNA; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CLAVULANIC ACID; DEOXYERYTHRONOLIDE B SYNTHASE; ENOYL REDUCTASE; ERYTHROMYCIN; GAMMA GLUTAMYLTRANSFERASE; HYDROLYASE; KETOREDUCTASE; LEAD; MACROLIDE; METICILLIN; MULTIDRUG RESISTANCE PROTEIN; OXAZOLIDINONE DERIVATIVE; OXIDOREDUCTASE; PEPTIDE SYNTHASE; POLYKETIDE SYNTHASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SYNTHETASE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIAL VIRULENCE; COMBINATORIAL CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG IDENTIFICATION; DRUG TARGETING; ENTEROBACTERIACEAE; GENE CLUSTER; GENE IDENTIFICATION; GENE MUTATION; GENETIC RECOMBINATION; GENOME ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR GENETICS; MOLECULAR INTERACTION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; FORECASTING; GENE EXPRESSION REGULATION, BACTERIAL; GENOME, BACTERIAL; GENOMICS; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0038441346     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrg1084     Document Type: Review

References (150)

1. McDermott, W. & Rogers, D. E. Social ramifications of control of microbial disease. Johns Hopkins Med. J. 151, 302-312 (1982).
2. Lowy, F. D. Staphylococcus aureus infections. N. Engl. J. Med 339, 520-532 (1998).
3. Hiramatsu, K. et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40, 135-136 (1997).
4. Staphylococcus aureus resistant to vancomycin - United States, 2002. Morb. Mortal. Wkly Rep. 51, 565-567 (2002).
5. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. Morb. Mortal. Wkly Rep. 51, 902 (2002). References 4 and 5 are the first reports of high-level vancomycin resistance that is caused by the vanA gene cluster in Staphylococcus aureus.
6. Loddenkemper, R., Sagebiel, D. & Brendel, A. Strategies against multidrug-resistant tuberculosis. Eur. Respir. J. (Suppl.) 36, 66-77 (2002).
7. Chan, E. D. & Iseman, M. D. Current medical treatment for tuberculosis. BMJ 325, 1282-1286 (2002).
8. Gonzales, R. D. et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357, 1179 (2001).
9. Bradford, P. A. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14, 933-951 (2001).
10. Garau, J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect. Dis. 2, 404-415 (2002).
11. Walsh, C. Molecular mechanisms that confer antibacterial drug resistance. Nature 406, 775-781 (2000).
12. Lipsitch, M. The rise and fall of antimicrobial resistance. Trends Microbiol. 9, 438-444 (2001). A review of the multitude of factors that influence the prevalence of antibiotic resistance in hospitals and the community.
13. LeClerc, J. E., Li, B., Payne, W. L. & Cebula, T. A. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 274, 1208-1211 (1996).
14. Schaaff, F., Reipert, A. & Bierbaum, G. An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 46, 3540-3548 (2002).
15. O'Brien, T. F. Emergence, spread, and environmental effect of antimicrobial resistance; how use of an antimicrobial anywhere can increase resistance to any antimicrobial anywhere else. Clin. Infect. Dis. 34 (Suppl.), 78-84 (2002).
16. Woodford, N. Glycopeptide-resistant enterococci: a decade of experience. J. Med. Microbiol. 47, 849-862 (1998).
17. Austin, D. J., Kristinsson, K. G. & Anderson, R. M. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc. Natl Acad. Sci. USA 96, 1152-1156 (1999).
18. Grundmann, H., Hori, S., Winter, B., Tami, A. & Austin, D. J. Risk factors for the transmission of methicillin-resistant Staphylococcus aureus in an adult intensive care unit: fitting a model to the data. J. Infect. Dis. 185, 481-488 (2002).
19. Mellon, M., Benbrook, C. & Benbrook, K. Hogging it: estimates of antimicrobial use in livestock. (Univ. South Carolina Publications, Cambridge, Massachusetts, USA, 2001).
20. Bottger, E. C., Springer, B., Pletschette, M. & Sander, P. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nature Med. 4, 1343-1344 (1998).
21. Andersson, D. I. & Levin, B. R. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 2, 489-493 (1999).
22. Nagaev, I., Bjorkman, J., Andersson, D. I. & Hughes, D. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol. Microbiol. 40, 433-439 (2001). Evidence that secondary mutations to compensate for the biological fitness costs of antibiotic resistance arise in nature.
23. Feikin, D. R. & Klugman, K. P. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin. Infect. Dis. 35, 547-555 (2002).
24. Oliveira, D. C., Tomasz, A. & de Lencastre, H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillin-resistant Staphylococcus aureus. Lancet Infect. Dis. 2, 180-189 (2002). References 23 and 24 show that these successful pathogens have little genetic diversity, which indicates that they might be vulnerable to genomics-based targeting.
25. Chalker, A. F. & Lunsford, R. D. Rational identification of new antibacterial drug targets that are essential for viability using a genomics-based approach. Pharmacol. Ther. 95, 1-20 (2002).
26. Thanassi, J. A., Hartman-Neumann, S. L., Dougherty, T. J., Dougherty, B. A. & Pucci, M. J. Identification of 113 conserved essential genes using a high-throughput gene disruption system in Streptococcus pneumoniae. Nucleic Acids Res. 30, 3152-3162 (2002).
27. Sa-Leao, R., Tomasz, A., Santos Sanches, I. & de Lencastre, H. Pilot study of the genetic diversity of the pneumococcal nasopharyngeal flora among children attending day care centers. J. Clin. Microbiol. 40, 3577-3585 (2002).
28. Sa-Leao, R., Vilhelmsson, S. E., de Lencastre, H., Kristinsson, K. G. & Tomasz, A. Diversity of penicillin-nonsusceptible Streptococcus pneumoniae circulating in Iceland after the introduction of penicillin-resistant clone Spain(6B)-2. J. Infect. Dis. 186, 966-975 (2002).
29. Gerdes, S. Y. et al. From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways. J. Bacteriol. 184, 4555-4572 (2002).
30. Akerley, B. J. et al. A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae. Proc. Natl Acad. Sci. USA 99, 966-971 (2002).
31. Ji, Y. et al. Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science 293, 2266-2269 (2001). An interesting example of target validation using the expression of antisense RNA to silence genes.
32. Knowles, D. J. New strategies for antibacterial drug design. Trends Microbiol. 5, 379-383 (1997).
33. Merrell, D. S. & Camilli, A. Detection and analysis of gene expression during infection by in vivo expression technology. Phil. Trans. P. Soc. Lond. B 355, 587-599 (2000).
34. Valdivia, R. H. & Falkow, S. Fluorescence-based isolation of bacterial genes expressed within host cells. Science 277, 2007-2011 (1997).
35. Hensel, M. et al. Simultaneous identification of bacterial virulence genes by negative selection. Science 269, 400-403 (1995). The original paper that describes signature-tagged mutagenesis (STM), possibly the most popular target-validation technique.
36. Mecsas, J. Use of signature-tagged mutagenesis in pathogenesis studies. Curr. Opin. Microbiol. 5, 33-37 (2002).
37. Herbert, M. A. et al. Signature tagged mutagenesis of Haemophilus influenzae identifies genes required for in vivo survival. Microb. Pathog. 33, 211-223 (2002).
38. Mei, J. M., Nourbakhsh, F., Ford, C. W. & Holden, D. W. Identification of Staphylococcus aureus virulence genes in a murine model of bacteraemia using signature-tagged mutagenesis. Mol. Microbiol. 26, 399-407 (1997).
39. Garvis, S., Mei, J.M., Ruiz-Albert, J. & Holden, D. W. Staphylococcus aureus svrA: a gene required for virulence and expression of the agr locus. Microbiology 148, 3235-3243 (2002).
40. Bahrani-Mougeot, F. K. et al. Type 1 fimbriae and extracellular polysaccharides are preeminent uropathogenic Escherichia coli virulence determinants in the murine urinary tract. Mol. Microbiol. 45, 1079-1093 (2002).
41. Lehoux, D. E., Sanschagrin, F. & Levesque, R. C. Identification of in vivo essential genes from Pseudomonas aeruginosa by PCR-based signature-tagged mutagenesis. FEMS Microbiol. Lett. 210, 73-80 (2002).
42. Autret, N., Dubail, I., Trieu-Cuot, P., Berche, P. & Charbit, A. Identification of new genes involved in the virulence of Listeria monocytogenes by signature-tagged transposon mutagenesis. Infect Immun. 69, 2054-2065 (2001).
43. Sun, Y. H., Bakshi, S., Chalmers, R. & Tang, C. M. Functional genomics of Neisseria meningitidis pathogenesis. Nature Med. 6, 1269-1273 (2000).
44. Camacho, L. R., Ensergueix, D., Perez, E., Gicquel, B. & Guilhot, C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol. Microbiol. 34, 257-267 (1999).
45. Cox, J. S., Chen, B., McNeil, M. & Jacobs, W. R. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 402, 79-83 (1999).
46. Merrell, D. S., Hava, D. L. & Camilli, A. Identification of novel factors involved in colonization and acid tolerance of Vibrio cholerae. Mol. Microbiol. 43, 1471-1491 (2002).
47. Hava, D. L. & Camilli, A. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors, Mol. Microbiol. 45, 1389-1406 (2002).
48. Lau, G. W. et al. A functional genomic analysis of type 3 Streptococcus pneumoniae virulence. Mol. Microbiol. 40, 555-571 (2001). References 47 and 48 describe the validafion validation of a large number of genetic targets in an important pathogen with serious antibiotic-resistance problems.
49. Wilson, M. etal. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization, Proc. Natl Acad. Sci. USA 96, 12833-12838 (1999).
50. Tao, J. et al. Drug target validation: lethal infection blocked by inducible peptide. Proc. Natl Acad. Sci. USA 97, 783-786 (2000). A new and successful target-validation method that also facilitates the subsequent search for inhibitor molecules.
51. Brown, M.J. et al. Rational design of femtomolar inhibitors of isoleucyl tRNA synthetase from a binding model for pseudomonic acid-A. Biochemistry 39, 6003-6011 (2000).
52. Jarvest, R. L. et al. Potent synthetic inhibitors of tyrosyl tRNA synthetase derived from C-pyranosyl analogues of SB- 219383. Bioorg. Med. Chem. Lett. 11, 715-718 (2001).
53. Stefanska, A. L., Fulston, M., Houge-Frydrych, C. S., Jones, J. J. & Warr, S. R. A potent seryl tRNA synthetase inhibitor SB-217452 isolated from a Streptomyces species. J. Antibiot. 53, 1346-1353 (2000).
54. Donadio, S. et a4 Microbial technologies for the discovery of novel bioactive metabolites. J. Biotechnol. 99, 187-198 (2002).
55. Blondelle, S. E., Perez-Paya, E. & Houghten, R. A. Synthetic combinatorial libraries: novel discovery strategy for identification of antimicrobial agents. Antimicrob. Agents Chemother. 40, 1067-107 t (1996).
56. Dolle, R. E. Comprehensive survey of combinatorial library synthesis: 2001. J. Comb. Chem. 4, 369-418 (2002).
57. Silen, J. L. et al. Screening for novel antimicrobials from encoded combinatorial libraries by using a two-dimensional agar format. Antimicrob. Agents Chemother. 42, 1447-1453 (1998).
58. Erlanson, D. A. et al. Site-directed ligand discovery. Proc. Natl Acad. Sci. USA 97, 9367-9372 (2000).
59. Wyatt, P. G. et al. Structure-activity relationship investigations of a potent and selective benzodiazepine oxytocin antagonist. Bioorg. Med. Chem. Lett. 11, 1301-1305 (2001).
60. Wyatt, P. G. et al. Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives. Bioorg. Med. Chem. Lett. 12, 1399-1404 (2002).
61. Schreiber, S. L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964-1969 (2000). A good review of alternative approaches to combinatorial chemistry.
62. Kuruvilla, F. G., Shamji, A. F., Sternson, S. M., Hergenrother, P. J. & Schreiber, S. L. Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature 416, 653-657 (2002).
63. Koza, D. J. Synthesis of 7-substituted tetracycline derivatives. Org. Lett. 2, 815-817 (2000).
64. Akritopoulou-Zanze, I. & Sowin, T. J. Solid-phase synthesis of macrolide analogues. J. Comb. Chem. 3, 301-311 (2001).
65. Gordeev, M. F. Combinatorial lead discovery and optimization of antimicrobial oxazolidinones. Curr. Opin. Drug Discov. Devel. 4, 450-461 (2001).
66. Sofia, M. J. el al. Discovery of novel disaccharide antibacterial agents using a combinatorial library approach. J. Med. Chem. 42, 3193-3198 (1999).
67. Baizman, E. R. et al. Antibacterial activity of synthetic analogues based on the disaccharide structure of moenomycin, an inhibitor of bacterial transglycosylase. Microbiology 146, 3129-3140 (2000).
68. Trias, J. The role of combichem in antibiotic discovery. Curr. Opin. Microbiol. 4, 520-525 (2001). A comprehensive review of the methods and successes in combinatorial chemistry applied to identifying new antibiotics.
69. Klebe, G. Recent developments in structure-based drug design. J. Mol. Med. 78, 269-281 (2000).
70. Clements, J. M. et al. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. 45, 563-570 (2001).
71. Hackbarth, C. J. et al. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother. 46, 2752-2764 (2002). References 70 and 71 describe the use of a target-based screen and structure-based drug design to isolate a new antibiotic class.
72. Lim, D. & Strynadka, N. C. Structural basis for the β-lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nature Struct. Biol. 9, 870-876 (2002). An important insight into the structural basis of β-lactam resistance that shows, in detail, how to design new drugs.
73. Rodriguez, E. & McDaniel, R. Combinatorial biosynthesis of antimicrobials and other natural products. Curr. Opin. Microbiol. 4, 526-534 (2001). A good review of the methods and potential of combinatorial biology in the search for new antibiotics.
74. Baltz, R. in Antibiotic Development and Resistance (eds Hughes, D. & Andersson, D. I.) 233-257 (Taylor and Francis, London, New York, 2001).
75. Cane, D. E., Walsh, C. T. & Khosla, C. Harnessing the biosynthetic code: combinations, permutations, and mutations. Science 282, 63-68 (1998).
76. Cane, D. E. & Walsh, C. T. The parallel and convergent universes of polyketide synthases and nonribosomal peptide synthetases. Chem. Biol. 6, 319-325 (1999).
77. McDaniel, R. et al. Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel 'unnatural' natural products. Proc. Natl Acad. Sci. USA 96, 1846-1851 (1999).
78. Losey, H. C. et al. Incorporation of glucose analogs by GtfE and GtfD frorn the vancomycin biosynthetic pathway to generate variant glycopeptides Chem. Biol. 9, 1305-1314 (2002).
79. Kwon, H. J. et al. C-O bond formation by polyketide synthases. Science 297, 1327-1330 (2002).
80. Miller, L. A., Ratnam, K. & Payne, D. J. β-lactamase-inhibitor combinations in the 21st century: current agents and new developments. Curr. Opin. Pharmacol. 1, 451-458 (2001).
81. Nikaido, H. Multiple antibiotic resistance and efflux. Curr. Opin. Microbiol. 1, 516-523 (1998).
82. Alekshun, M. N. & Levy, S. B. Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon. Antimicrob. Agents Chemother. 41, 2067-2075 (1997).
83. Markham, P. N., Westhaus, E., Klyachko, K., Johnson, M. E. & Neyfakh, A. A. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob. Agents Chemother. 43, 2404-2408 (1999).
84. Gibbons, S., Oluwatuyi, M. & Kaatz, G. W. A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus. J. Antimicrob. Chemother. 51, 13-17 (2003).
85. Kaatz, G. W., Moudgal, V. V. Seo, S. M. & Kristiansen, J. E. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 719-726 (2003).
86. Nelson, M. L. & Levy, S. B. Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein. Antimicrob. Agents Chemother. 43, 1719-1724 (1999).
87. Renau, T. E. et al. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J. Med. Chem. 42, 4928-4931 (1999).
88. Lomovskaya, O. et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45, 105-116 (2001). An important primary research paper that identified active efflux-pump inhibitors that are now under development.
89. Murakami, S., Nakashima, R., Yamashita, E. & Yamaguchi, A. Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 419, 587-593 (2002).
90. Mao, W. el al. On the mechanism of substrate specificity by resistance nodulation division (RND)-type multidrug resistance pumps: the large periplasmic loops of MexD from Pseudomonas aeruginosa are involved in substrate recognition. Mol. Microbiol. 46, 889-901 (2002).
91. Bjorkman, J., Hughes, D. & Andersson, D. I. Virulence of antibiotic-resistant Salmonella typhimurium. Proc. Natl Acad. Sci. USA 95, 3949-3953 (1998).
92. Sander, P. et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob. Agents Chemother. 46, 1204-1211 (2002).
93. Johanson, U., Aevarsson, A., Liljas, A. & Hughes, D. The dynamic structure of EF-G studied by fusidic acid resistance and internal revertants. J. Mol. Biol. 258, 420-432 (1996).
94. Bjorkman, J., Samuelsson, R, Andersson, D. I. & Hughes, D. Novel ribosomal mutations affecting translational accuracy, antibiotic resistance and virulence of Salmonella typhimurium. Mol. Microbiol. 31, 53-58 (1999).
95. Bjorkman, J., Nagaev, I., Berg, O. G., Hughes, D. & Andersson, D. I. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287, 1479-1482 (2000).
96. Schrag, S. J. & Perrot, V. Reducing antibiotic resistance. Nature 381, 120-121 (1996).
97. Reynolds, M. G. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 156, 1471-1481 (2000).
98. Hanson, N. D. & Sanders, C. C. Regulation of inducible AmpC β-lactamase expression among Enterobacteriaceae. Curr. Pharm. Des. 5, 881-894 (1999).
99. Baptista, M., Depardieu, F., Courvalin, P. & Arthur, M. Specificity of induction of glycopeptide resistance genes in Enterococcus faecalis. Antimicrob. Agents Chemother. 40, 2291-2295 (1996).
100. Seppala, H. et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N. Engl. J. Med. 337, 441-446 (1997).
101. Nissinen, A. et al. Development of β-lactamase-mediated resistance to penicillin in middle-ear isolates of Moraxella catarrhalis in Finnish children, 1978-1993. Clin. Infect. Dis. 21, 1193-1196 (1995).
102. Kristinsson, K. G. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Microb. Drug Resist. 3, 117-123 (1997).
103. Lipsitch, M., Bergstrom, C. T. & Levin, B. R. The epidemiology of antibiotic resistanse in hospitals: paradoxes and prescriptions. Proc. Natl Acad. Sci. USA 97, 1938-1943 (2000).
104. Bonten, M. J., Austin, D. J. & Upsitch, M. Understanding the spread of antibiotic resistant pathogens in hospitals: mathematical models as tools for control. Clin. Infect. Dis. 33, 1739-1746 (2001).
105. Boissinot, M. & Bergeron, M. G. Toward rapid real-time molecular diagnostic to guide smart use of antimicrobials. Curr. Opin. Microbiol. 5, 478-482 (2002).
106. Schweitzer, B. & Kingsmore, S. Combining nucleic acid amplification and detection. Curr. Opin. Biotechnol. 12, 21-27 (2001).
107. Fluit, A. C., Visser, M. R. & Schmitz, F. J. Molecular detection of antimicrobial resistance. Clin. Microbiol. Rev. 14, 836-871 (2001).
108. Garcia de Viedma, D. et al. New real-time PCR able to detect in a single tube multiple rifampin resistance mutations and high-level isoniazid resistance mutations in Mycobacterium tuberculosis. J. Clin. Microbiol. 40, 988-995 (2002).
109. Grohs, P., Kitzis, M. D. & Gutmann, L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 418-420 (2003).
110. Fattorini, L. et al. Activities of moxilloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. Antimicrob. Agents Chemother. 47, 360-362 (2003).
111. Zhao, X. & Drlica, K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroculnolone studies. Clin. Infect. Dis. 33 (Suppl.), 147-156 (2001).
112. Zhao, X. & Drlica, K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185, 561-565 (2002).
113. Blondeau, J. M., Zhao, X., Hansen, G. & Drlica, K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45, 433-438 (2001).
114. Heath, P. T. & McVernon, J. The UK Hib vaccine experience. Arch. Dis. Child. 86, 396-399 (2002).
115. Ramsay, M. E., Andrews, N., Kaczmarski, E. B. & Miller, E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357, 195-196 (2001).
116. Obaro, S. K. The new pneumococcal vaccine. Clin. Microbiol. Infect. 8, 623-633 (2002). References 114-116 describe the isolation and successful use of vaccines against important pathogens.
117. Shinefield, H. et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346, 491-496 (2002).
118. Fraser, C. M., Eisen, J., Fleischmann, R. D., Kelchum, K. A. & Peterson, S. Comparative genomics and understanding of microbial biology. Emerg. Infect. Dis. 6, 505-512 (2000).
119. Moxon, E. R., Hood, D. W., Saunders, N. J., Schweda, E. K. & Richards, J. C. Functional genomics of pathogenic bacteria. Phil. Trans. R. Soc. Lond. B 357, 109-116 (2002).
120. Wizemann, T M. et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69, 1593-1598 (2001).
121. Pizza, M. et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816-1820 (2000).
122. Comanducci, M. et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195, 1445-1454 (2002).
123. Cockle, P. J. et al. Identification of novel Mycobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics. Infect. Immun. 70, 6996-7003 (2002).
124. Pollard, A. J. & Moxon, E. R. The meningococcus tamed? Arch. Dis. Child. 87, 13-17 (2002).
125. Sulakvelidze, A., Alavidze, Z. & Morris, J. G. Bactedophage therapy. Antimicrob. Agents Chemother. 45, 649-659 (2001).
126. Bull, J. J., Levin, B. R., DeRouin, T., Walker, N. & Bloch, C. A. Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol. 2, 35 (2002).
127. Biswas, B. et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70, 204-210 (2002). The successful application of bacteriophage therapy in an in vivo model.
128. Abbanat, D., Macielag, M. & Bush, K. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert. Opin. Investig. Drugs 12, 379-399 (2003).
129. Allen, N. E. & Nicas, T. I. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26, 511-532 (2003).
130. Jones, R. N. Microbiology of newer fluoroquinolones: focus on respiratory pathogens. Diagn. Microbiol. Infect Dis. 44, 213-220 (2002).
131. Projan, S. J. New (and not so new) antibacterial targets - from where and when will the novel drugs come? Curr. Opin. Pharmacol. 2, 513-522 (2002). Pessimistic view of target-based screening from a pharmaceutical industry perspective.
132. Projan, S. J. & Youngman, P. J. Antimicrobials: new solutions badly needed. Curr. Opin. Microbiol. 5, 463-465 (2002).
133. Resnik, D. B. & De Ville, K. A. Bioterrorism and patent rights: 'compulsory licensure' and the case of Cipro. Am. J. Bioeth. 2, 29-39 (2002).
134. McDermott, P. F. et al. The food safety perspective of antibiotic resistance. Anim. Biotechnol. 13, 71-84 (2002).
135. Pugh, D. M. The EU precautionary bans of animal feed additive antibiotics. Toxicol. Lett. 128, 35-44 (2002).
136. De, E. et al. A new mechanism of antibiotic resistance in Enterobacteriaceae induced by a structural modification of the major porin. Mol. Microbiol. 41, 189-198 (2001).
137. Poole, K. Multidrug resistance in Gram-negative bacteria. Curr. Opin. Microbiol. 4, 500-508 (2001).
138. Markham, P. N. & Neyfakh, A. A. Efflux-mediated drug resistance in Gram-positive bacteria. Curr. Opin. Microbiol. 4, 509-514 (2001).
139. Hooper, D. C. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. 7, 337-341 (2001).
140. Roberts, M. C. et al. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob. Agents Chemother. 43, 2823-2830 (1999).
141. Hakenbeck, R. et al. Mosaic genes and mosaic chromosomes: intra- and interspecies genomic variation of Streptococcus pneumoniae. Infect. Immun. 69, 2477-2486 (2001).
142. Perichon, B. & Courvalin, P. Update on vancomycin resistance. Int. J. Clin. Pract. (Suppl.) 88-93 (2000).
143. Donadio, S., Staver, M. J., McAlpine, J. B., Swanson, S. J. & Katz, L. Modular organizalion of genes required for complex polyketide biosynthesis. Science 252, 675-679 (1991).
144. Tsuji, S. Y., Wu, N. & Khosla, C. Intermodular communication in polyketide synthases: comparing the role of protein-prolein interactions to those in other multidomain proteins. Biochemistry 40, 2317-2325 (2001).
145. Xue, Q., Ashley, G., Hutchinson, C. R. & Santi, D. V. A multiplasmid approach to preparing large libraries of polyketides. Proc. Natl Acad. Sci. USA 96, 11740-11745 (1999).
146. Pohl, N. L. Nonnatural substrates for polyketide synthases and their associated modifying enzymes. Curr. Opin. Chem. Biol. 6, 773-778 (2002).
147. Shlaes, D. M. & Moellering, R. C. The United States Food and Drug Administration and the end of antibiotics. Clin. Infect. Dis. 34, 420-422 (2002).
148. Fletcher, L. Cubist highlights FDA's antibiotic resistance. Nature Biotech. 20, 206-207 (2002).
149. Powers, J. H., Ross, D. B., Brittain, E., Albrecht, R. & Goldberger, M. J. The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents. Clin. Infect. Dis. 34, 879-881 (2002).
150. Arthur, M. et al. Mechanisms of glycopeptide resistance in enterococci. J Infect. 32, 11-16 (1996).